Introduction {#s1}
============

Migraine is a common, chronic neurovascular disorder characterized by severe, debilitating headaches that can last for several hours, or even days. It is often accompanied by nausea, vomiting and other neurological symptoms, such as light and noise sensitivity and visual aura. These symptoms are often disabling and affect the patient's ability to function normally \[[@B1]\]. As a chronic condition, migraines recur throughout a patient\'s life \[[@B2]\].

Several migraine treatments are available: some are effective to address pain (analgesics, non-steroidal anti-inflammatory drugs (NSAIDS), and caffeine), and other aim at preventing migraines from happening. The latter include ergotamine and pethidine, but more specific migraine therapies are triptans (selective 5-hydroxytryptamine serotonin receptor agonists). Although triptans differ in their ability to prevent a recurrence of migraine, they are considered equally effective in their ability to provide relief, and are recommended as first line therapies for moderate to severe attacks \[[@B1]\]. However the majority of migraine sufferers still use over-the-counter (OTC) medications such as analgesics, or non-steroidal anti-inﬂammatory drugs (NSAIDs), such as aspirin, ibuprofen, or naproxen sodium \[[@B3]\].

It is estimated that 10% to 15% of people worldwide suffer from migraine at one point during their lives \[[@B4]\]. Migraine was listed by the World Health Organization (WHO) in the Global Burden of Disease Study 2000 as the 19^th^ highest cause of disability (12^th^ in women). Migraine has been acknowledged by WHO as a priority for development of effective treatments \[[@B5]\]. Management of the disease presents a substantial economic burden for society in terms of use of intensive health care resources (general practitioner (GP) and emergency room (ER) visits), as well as lost productivity as most sufferers are between 25 and 55 \[[@B4]\]. The annual cost of migraine has been estimated to be €27 billion in Europe, \$US1.4 billion in the UK and \$US16.6 billion in the US \[[@B6]\].

Medical professional societies in many countries have published clinical practice guidelines, which aim to improve the quality of care migraine patients receive by providing evidence-based recommendations to health care providers. Some guidelines target headaches of all kinds, including migraine (UK \[[@B7]\], Scotland \[[@B8]\], Croatia \[[@B9]\], Switzerland \[[@B10]\], Romania \[[@B11]\]). Others concern migraine alongside tension and cluster headache (Denmark \[[@B12]\], Italy \[[@B13]\]). Still others specifically target migraine management (Spain \[[@B14]\] and France \[[@B15]\]).

Primary headaches such as migraine with or without aura and episodic tension-type headache can be treated by patients themselves, without a health care provider intermediary \[[@B16]\]. For example, the OTC products aspirin (acetylsalicylic acid), paracetamol (acetaminophen), and non-steroidal anti-inflammatory drugs (NSAIDs) can be used to treat migraine. Nevertheless, many clinicians believe that the therapeutic class of triptans is clinically more effective for acute migraine \[[@B17]\]. In 2006, sumatriptan 50mg and naratriptan 2.5mg were approved as OTC drugs in the UK and Germany, respectively, following studies which demonstrated their safe and effective use in large numbers of migraine patients \[[@B18]\]. However, the economic impact of the switch of these two triptans in either market has not been studied to date.

Several benefits are expected in case of an Rx-to-OTC switch for triptans. First, OTC availability will allow early, convenient access to effective therapies, in particular, the ability to self-medicate when a migraine is in its early onset stage -- all medications are more effective at this stage than when the headache has progressed to one with more severe symptoms \[[@B19]\]. Second, easier access may result in improved outcomes and better worker productivity. Third, cost savings are expected from avoided GP and emergency room visits and lower drug prices. Nevertheless Rx-to-OTC switch has some limits, including the lack of proper monitoring that may lead to excessive use or misuse, or contraindicated use \[[@B20]--[@B23]\]. This may mitigate the clinical and economic benefits, unless phamarcist supervision is considered.

Given that migraine sufferers tend to be able to self-diagnose and self-manage their condition \[[@B24]\], the availability of OTC triptan might be a cost-effective alternative. The main objective of this study is to assess the economic impact of a triptan Rx-to-OTC switch.

Methods {#s2}
=======

Study design {#s2.1}
------------

We estimated the impact of a potential switch of a triptan from prescription status to non-prescription status, in France, UK, Spain, Italy, Germany and Poland.

We constructed a decision model to compare the current situation to the potential scenario in which a triptan is switched to OTC availability. The analysis was applied to several hypothetical cohorts of patients suffering from migraine. The simulations were performed from two decision-making perspectives: a third-party payer (TPP) and a societal perspective.

The timeframe of the analysis is one year from the moment of a potential switch and represents the savings at the forecast peak uptake of the switched-to-OTC triptan.

Model Development {#s2.2}
-----------------

We used the checklist published by Cohen et al. \[[@B25]\] to develop our model, and followed their recommendations. Three distinct components of the modeling process are covered: structural issues on decision context, health states and clinical outcomes, and other considerations for model specifications.

### 1: Structural issues on decision context {#s2.2.1}

1.  **Pathology** Migraine is a chronic condition with acute exacerbations that results in recurrent headache and patient disability. Treatments, such as the therapeutic class of triptans, are available which relieve pain and associated symptoms to allow sufferers to recover and resume normal daily activities. While triptans are only taken during the migraine attacks (therefore not pre-emptively or prophylactically), their timely uptake is crucial, as the literature suggests that the earlier treatment is taken the better is the therapeutic effect \[[@B26]\]. Results from three retrospective analyses of the effectiveness of early treatment with sumatriptan shows that early treatment (while pain is generally still mild) significantly improves the pain free response \[[@B19]\]. These studies point to an additional benefit: fewer patients require treatment re-dosing, which translates into less medication use and consequently lower pharmaceutical costs.

2.  **Triptan class of drugs** The long term safety of triptans has been validated \[[@B27]\]. Even in instances in which triptans are contraindicated in patients presenting with cardiac or cerebrovascular diseases, triptans have been shown to be safer than other treatment alternatives, such as serotonin-agonist ergot preparations, morphine or pethidine\[[@B18]\]. Moreover, other options may pose a risk to certain patients, as aspirin and non-steroidal anti-inflammatory drugs may cause gastro-intestinal hemorrhage \[[@B18]\].

3.  **Populations** Among the population suffering from migraine, six subgroups were selected: Pop 1 (diagnosed, treated with Rx triptan to be switched), Pop 2 (diagnosed, treated with other Rx triptans), Pop 3 (diagnosed, treated with OTC), Pop 4 (diagnosed untreated), Pop 5 (undiagnosed, treated with OTC), Pop 6 (undiagnosed, untreated). Population of patients being prescribed Rx drugs other than triptans were not included.

### 2: Health states and clinical outcomes {#s2.2.2}

1.  **Epidemiology** Country-specific data are available on national statistics websites, which may be complemented by trade- and peer-reviewed literature searches.

2.  **Health outcomes** Given that the main objective of this analysis is to estimate the economic impact of a triptan Rx-to-OTC switch, and not the health benefit, the model did not include health outcomes. On the other hand, serious adverse events were considered, in particular, cardiovascular events that may occur when undiagnosed patients switch to OTC triptan. Only economic impact of serious adverse events was included in the model.

3.  **Resource utilisation** The model includes direct and indirect costs. Direct costs comprise drug acquisition costs, cost of GP and ER visits, as well as costs due to serious adverse events. Indirect costs refer to productivity losses owing to time off from work.

    From the TPP perspective, the model includes direct costs savings (less money spent on Rx drug acquisition, fewer GP and ER visits due to easier access to an effective therapy). The societal perspective also includes indirect costs savings (less absenteeism and improved employee productivity).

### 3: Other considerations for model specifications {#s2.2.3}

1.  **Patient behaviour** The model assumes that the patient will not require a doctor visit with the OTC drug.

2.  **OTC switch rate** There is no published evidence on switch rates for triptans in migraine. Therefore, assumptions were made based on estimates from previous examples of Rx-to-OTC switches in Europe. Here, it was necessary to distinguish between patients currently taking Rx triptan to be switched, those on any other triptan, those taking OTC drugs at the time of migraine attacks, and those not using any pharmaceutical agents. The base-case model assumes that following the switch, the switched triptan retains a 'dual reimbursement status' (available without a prescription and not reimbursed, or reimbursed if prescribed).

3.  **Misuse** Medication-overuse headache (MOH) is a serious and disabling disorder. We considered the implications of MOH in the model in terms of additional GP visits and additional productivity losses.

Input data {#s2.3}
----------

Input data include epidemiological and resource utilization data.

### 1: Epidemiological Data {#s2.3.1}

1.  **Populations** This section presents the methodology used to estimate the numbers of patients of each sub-population. First we estimated the total country population aged over 18, and applied a country-specific migraine prevalence rate to calculate disease incidence. Then we used a diagnosis rate, to distinguish between the diagnosed and the undiagnosed patient populations. We created a treatment algorithm based on publically available prescription patterns as well as sales data. For diagnosed patients, we identified treated and untreated migraine patients. Subsequently, for the treated population, we estimated the population sizes depending on their treatment strategies (Rx, both Rx and OTC, or untreated). Finally, by combining these estimates with sales data of triptan to be switched and other Rx triptans, we ended up with an approximate size of patients in Pop 1, Pop 2, Pop 3, and Pop 4. For the undiagnosed patients, we assumed that the percentage of treated patients (OTC, self-treated) corresponds to the percentage of those diagnosed and treated. This allowed an estimation of the size of Pop 5 and Pop 6.

2.  **Switch rates** Switch rates were mainly based on estimates from past examples of Rx-to-OTC switches in Europe. These were obtained from internal pharmaceutical sales data sources. In the base case scenario we assumed the peak uptake of OTC triptan to be switched would be 20% among both patients currently taking the Rx triptan and those on any other triptan, and 3% among patients either diagnosed with triptan but currently taking OTC drugs at the time of migraine attacks, or not using any pharmaceutical treatments. No distinction was found in the literature to support a country-specific switch rate.

    [Table 1](#pone-0084088-t001){ref-type="table"} presents the epidemiological inputs included in the model.
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###### Epidemiological inputs included in the model.

                                                                                                                               **France**   **UK**                 **Italy**    **Germany**   **Poland**   **Spain**    **Source**                                                       
  ---------------------------------------------------------------------------------------------------------------------------- ------------ ---------------------- ------------ ------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  **Population**                                                                                                                                                                                                                                                                         
  Population size                                                                                                              62,616,488   61,792,000             60,221,211   81,879,976    38,149,886   45,957,671   \[[@B36]\]   \[[@B38]\]   \[[@B36]\]   \[[@B36]\]   \[[@B36]\]   \[[@B36]\]
  Population over 18 years old                                                                                                 78%          77%                    83%          84%           81%          82%          \[[@B37]\]   \[[@B38]\]   \[[@B39]\]   \[[@B40]\]   \[[@B41]\]   \[[@B42]\]
  Migraine prevalence                                                                                                          21.3%        15%                    11.6%        10.0%         10.0%        12.6%        \[[@B43]\]   \[[@B35]\]   \[[@B44]\]   \[[@B45]\]   \[[@B46]\]   \[[@B47]\]
  Adults with migraine population                                                                                              10,403,103   7,136,976              5,798,098    6,877,918     3,090,141    4,748,347    \-           \-           \-           \-           \-           \-
  **Diagnosis rates and prescription patterns**                                                                                                                                                                                                                                          
  Diagnosis rate                                                                                                               75%          65%                    50%          50%           50%          50%          \[[@B48]\]   \[[@B49]\]   \[[@B50]\]   \[[@B50]\]   \[[@B50]\]   \[[@B50]\]
  Diagnosed patients                                                                                                           7,802,327    4,639,034              2,899,049    3,438,959     1,545,071    2,374,174    \-           \-           \-           \-           \-           \-
  \% treated                                                                                                                   90%          89%                    90%          90%           90%          90%          \[[@B51]\]   \[[@B52]\]   \[[@B51]\]   \[[@B51]\]   \[[@B51]\]   \[[@B51]\]
  Treated patients                                                                                                             7,022,094    4,128,740              2,609,144    3,095,063     1,390,564    2,136,757    \-           \-           \-           \-           \-           \-
  \% adult treated with Rx (w or w/o OTC drugs)                                                                                50%          41%                    50%          50%           50%          50%          \[[@B51]\]   \[[@B49]\]   \[[@B51]\]   \[[@B51]\]   \[[@B51]\]   \[[@B51]\]
  Adults treated with Rx (w or w/o OTC drugs)                                                                                  3,511,047    1,692,783              1,304,572    1,547,532     695,282      1,068,379    \-           \-           \-           \-           \-           \-
  \% adult treated with triptan                                                                                                25%          22%                    19%          31%           5%           18%          \[[@B53]\]   \[[@B53]\]   \[[@B53]\]   \[[@B53]\]   \[[@B53]\]   \[[@B53]\]
  \% adult treated with Rx triptan to be switched                                                                              35%          17%                    9%           23%           3%           29%          \[[@B53]\]   \[[@B53]\]   \[[@B53]\]   \[[@B53]\]   \[[@B53]\]   \[[@B53]\]
  Pop 1 (diagnosed, treated with Rx triptan to be switched)                                                                    309,354      62,793                 21,634       109,646       966          55,942       \-           \-           \-           \-           \-           \-
  Pop 2 (diagnosed, treated with other Rx triptans)                                                                            563,206      313,181                232,084      375,642       30,627       139,250      \-           \-           \-           \-           \-           \-
  Pop 3 (diagnosed, treated with OTC)                                                                                          3,511,047    2,435,957              1,304,572    1,547,532     695,282      1,068,379    \-           \-           \-           \-           \-           \-
  sPop 4 (diagnosed, untreated)                                                                                                780,233      510,294                289,905      343,896       154,507      237,417      \-           \-           \-           \-           \-           \-
  Undiagnosed patients                                                                                                         2,600,776    2,497,942              2,899,049    3,438,959     1,545,071    2,374,173    \-           \-           \-           \-           \-           \-
  \% treated with OTC (only)                                                                                                   90%          89%                    90%          90%           90%          90%          \[[@B51]\]   \[[@B49]\]   \[[@B51]\]   \[[@B51]\]   \[[@B51]\]   \[[@B51]\]
  Pop 5 (undiagnosed, treated with OTC)                                                                                        2,340,698    2,223,168              2,609,144    3,095,063     1,390,563    2,136,756    \-           \-           \-           \-           \-           \-
  Pop 6 (undiagnosed, not treated)                                                                                             260,078      274,774                289,905      343,896       154,507      237,417      \-           \-           \-           \-           \-           \-
  **Switch rates**                                                                                                                                                                                                                                                                       
  Pop 1 (diagnosed, treated with Rx triptan to be switched)                                                                    20%                                                                                                                                                       
  Pop 2 (diagnosed, treated with other Rx triptans)                                                                            20%          Base case assumption                                                                                                                         
  Pop 3 (diagnosed, treated with OTC)                                                                                          3%                                                                                                                                                        
  Pop 4 (diagnosed, untreated)                                                                                                 3%                                                                                                                                                        
  Pop 5 (undiagnosed, treated with OTC)                                                                                        0%                                                                                                                                                        
  Pop 6 (undiagnosed, not treated)                                                                                             0%                                                                                                                                                        
  **Adverse events**                                                                                                                                                                                                                                                                     
  \% of decrease in the risk of adverse events (thanks to label indications, pharmacist training) for Pop 3, Pop 5 and Pop 6   95%          Base case assumption                                                                                                                         

### 2: Resource Utilization {#s2.3.2}

Costs have been calculated depending on the population involved and the perspective selected. This section describes our calculation methods, the assumptions used, and [Table 2](#pone-0084088-t002){ref-type="table"} presents the main inputs used.

10.1371/journal.pone.0084088.t002

###### Resource utilization inputs included in the model.

                                                                                                         **France**   **UK**                                      **Italy**   **Germany**     **Poland**   **Spain**   **Source**                                                        
  ------------------------------------------------------------------------------------------------------ ------------ ------------------------------------------- ----------- --------------- ------------ ----------- ------------- ------------ ------------ ------------ ------------ ------------
  **Disease related assumption**                                                                                                                                                                                                                                                         
  Incidence of migraine attacks per patient per year                                                     24           \[[@B54]\]                                                                                                                                                         
  **Drug acquisition costs and reimbursement levels**                                                                                                                                                                                                                                    
  Triptan to be switched unit cost per attack                                                            €7.36        £6.92                                       €9.65       €6.46           PLN 16.6     €11.22      Calculation                                                       
  Other Rx triptans unit cost per attack                                                                 €6.12        £6.09                                       €8.05       €5.59           PLN 19.87    €9.25       Calculation                                                       
  Reimbusement rate triptan to be switched                                                               65%          100%                                        100%        100%            0%           100%        IMS data                                                          
  Reimbusement rate other Rx triptans                                                                    65%          100%                                        100%        100%            0%           100%        IMS data                                                          
  **GP visits**                                                                                                                                                                                                                                                                          
  Number of GP visits specifically for migraine per patient per year                                     2.8          \[[@B30]\]                                                                                                                                                         
  \% of unscheduled visits (i.e. visits exclusively to obtain prescription)                              30%          \[[@B55]\]                                                                                                                                                         
  Cost of a GP visit                                                                                     €22          £39                                         €21         €31             PLN 31       €23         \[[@B56]\]    \[[@B57]\]   \[[@B58]\]   \[[@B59]\]   \[[@B60]\]   \[[@B61]\]
  **Emergency room visit costs**                                                                                                                                                                                                                                                         
  Probability of ER visit per attack when treated with usual care (%)                                    0.4%         \[[@B31]\]                                                                                                                                                         
  Reduction in ER visits with triptans                                                                   65%          \[[@B31]\]                                                                                                                                                         
  Cost of migraine ER visit                                                                              €25          £51                                         €62         €53             PLN 147      €128        \[[@B62]\]    \[[@B57]\]   \[[@B55]\]   \[[@B63]\]   \[[@B64]\]   \[[@B65]\]
  **Serious adverse events**                                                                                                                                                                                                                                                             
  \% of triptan contraindicated patient                                                                  8%           \[[@B32]\]                                                                                                                                                         
  Incidence of serious adverse event                                                                     0.1%         \[[@B33]\]                                                                                                                                                         
  \% of decrease in the risk of serious AEs (thanks to label indications, pharmacist trainings)          95%          Expert assumption                                                                                                                                                  
  Average cost of a serious cardiovascular event                                                         €1,694       £1,916                                      €3,416      €3,610          PLN 2,927    €4,320      \[[@B66]\]    \[[@B67]\]   \[[@B68]\]   \[[@B69]\]   \[[@B70]\]   \[[@B71]\]
  **Productivity costs**                                                                                                                                                                                                                                                                 
  Number of days with migraine attack per patient per year (Pop 1 and Pop 2)                             24           \[[@B54]\]                                                                                                                                                         
  Number of days with migraine attack per patient per year (Pop 3,Pop 4, Pop 5 and Pop 6)                12           \[[@B35]\]                                                                                                                                                         
  \% of attacks during work hours                                                                        35%          \[[@B72]\]                                                                                                                                                         
  Probability of not having triptan at time of attack                                                    25%          \[[@B72]\]                                                                                                                                                         
  Absenteeism                                                                                                                                                                                                                                                                            
  \% of migraine attacks work days resulting in absenteeism (Pop 1 and Pop 2)                            24%          \[[@B73]\]                                                                                                                                                         
  \% of migraine attacks work days resulting in absenteeism (Pop 3, Pop 4, Pop 5 and Pop 6)              8%           \[[@B35]\]                                                                                                                                                         
  Presenteeism                                                                                                                                                                                                                                                                           
  \% of migraine attacks with symptoms affecting patient productivity (Pop 1 and Pop 2)                  73%          \[[@B35]\]                                                                                                                                                         
  \% of migraine attacks with symptoms affecting patient productivity (Pop 3, Pop 4, Pop 5 and Pop 6)    24%          \[[@B35]\]                                                                                                                                                         
  Productivity level of migraine patient while suffering from symptoms                                   56%          \[[@B74]\]                                                                                                                                                         
  \% increase in productivity during migraine attacks related to triptan use                             13%          \[[@B74]\]                                                                                                                                                         
  **Avoided time off work**                                                                                                                                                                                                                                                              
  \% of employed migraine sufferers                                                                      70%          \[[@B30]\]                                                                                                                                                         
  Average time missed due to a doctor visit (work days)                                                  0.5          \[[@B34]\]                                                                                                                                                         
  \% of visits made during work hours                                                                    25%          \[[@B34],[@B75]\]                                                                                                                                                  
  Average cost of one lost work day to the economy                                                       €127         £120                                        €107        €164            PLN 180      €94         \[[@B76]\]    \[[@B77]\]   \[[@B78]\]   \[[@B79]\]   \[[@B80]\]   \[[@B78]\]
  **Medication-overuse headache (MOH)**                                                                                                                                                                                                                                                  
  \% of triptan users likely to experience MOH                                                           14%          \[[@B81]\]                                                                                                                                                         
  \% of reduction in the risk of MOH thanks to smaller OTC packages and pharmacist training              95%          Expert assumption                                                                                                                                                  
  Additional number of GP visits due to MOH per patient per year                                         8.4          \[[@B82]\]                                                                                                                                                         
  Additional number of days with migraine attack per MOH patient per year                                108          Calculated from \[[@B81]\] and \[[@B83]\]                                                                                                                          
  Absenteism (% of lost work days resulting in absenteeism due to MOH)                                   24%          \[[@B84]\]                                                                                                                                                         
  Presenteism (% of migraine attacks in patients with MOH with symptoms affecting patient productivity   55%          \[[@B84]\]                                                                                                                                                         

1.  **Drug acquisition costs** Average cost per attack was calculated as cost per dose of triptan multiplied by mean doses per attack, weighted according to market share \[[@B28]\]. Cost per dose has been identified as being the drug acquisition cost divided by the number of doses in the pack. Mean dose by attack was set at 1.61, as stated by Guidotti et al. \[[@B29]\]. Reimbursement rate for all triptans by payers (without co-payment) was 100% before the switch Germany, Spain and Italy, 65% in France and 0% in Poland (0%).

2.  **GP visits** Number of migraine-specific GP visits per year was found to be 2.8 from a 2001 multinational survey (US and Europe) using a self-reported Migraine Background Questionnaire \[[@B30]\]. Of these visits, 30% were assumed to be unscheduled visits to obtain a prescription. We used country-specific unit costs of GP visits.

3.  **Emergency room visit costs** The probability of ER visit per attack when treated with usual care was found to be 0.4%, and the reduction in ER visits with triptan was found to be 65% \[[@B31]\]. We used country-specific unit costs of ER visits.

4.  **Serious adverse events** Percentage of patients presenting at least one contraindication to triptan was found to be 8% in a retrospective claims analysis study conducted in France \[[@B32]\]. Serious adverse events represented an overall incidence of 0.1% \[[@B33]\]. The percentage of decrease in the risk of serious AE thanks to label indications, and/or pharmacists training was assumed to be 95%. We used country-specific costs of serious AE.

5.  **Time off from work** We derived the estimated percentage (70%) of employed migraine patients from a survey conducted in 23 US and 78 non-US sites \[[@B30]\]. The average time missed due to a GP visit was derived from the Association of Great Britain \[[@B34]\], and was estimated to be 0.5 work days. We also used their estimation of percentage of visits made during working hours (25%). The average cost of one working day was country-specific. Cost savings due to avoided absenteeism was then computed as the number of days missed from work due to GP visits per year multiplied by the average country-specific cost of one working day.

6.  **Productivity losses** Cost savings due to avoided productivity losses were defined as number of missed work days avoided and of avoided missed work days exclusively lost due to presenteeism, multiplied by the average cost of one lost work day, weighted by the increase in work effectiveness during migraine attacks related to triptan use.

    The percentage of migraine attacks on work days that resulted in absenteeism was estimated to be 24% (a survey among English patients reported the average number of migraine attacks to be 24 and the average number of days lost to be 5.7 \[[@B35]\]. The same source indicated that the percentage of migraine attacks on work days with symptoms affecting patients' productivity was estimated to be 73%.

Sensitivity analyses {#s2.4}
--------------------

We depicted several scenarios to illustrate how the potential cost savings would vary depending on different switch rates.

### Scenarios A and B {#s2.4.1}

Given the uncertainties and the lack of relevant publically available evidence about past switches, switch rates were varied to analyze the potential impact on results. In scenario A switch rates for Pop 1 and Pop 2 were decreased to 0% instead of 20%. In scenario B switch rates for Pop 5 and Pop 6 were increased to 3% instead of 0%. This is summarized in [Table 3](#pone-0084088-t003){ref-type="table"}.

10.1371/journal.pone.0084088.t003

###### Scenarios around the switch rates.

  **Population**                                              **Base case scenario**   **Scenario A (switch rates)**   **Scenario B (switch rates)**
  ----------------------------------------------------------- ------------------------ ------------------------------- -------------------------------
  Pop 1 (diagnosed, treated with Rx triptan to be switched)   20%                      0%                              20%
  Pop 2 (diagnosed, treated with other Rx triptans)           20%                      0%                              20%
  Pop 3 (diagnosed, treated with OTC)                         3%                       3%                              3%
  Pop 4 (diagnosed untreated)                                 3%                       3%                              3%
  Pop 5 (undiagnosed treated with OTC)                        0%                       0%                              3%
  Pop 6 (undiagnosed not treated)                             0%                       0%                              3%

### Scenario C {#s2.4.2}

Clear labeling and pharmacists training were assumed to decrease cardiovascular event risk from 95%. This rate was varied to 90%, to illustrate the importance of incorporating measures/policies that could minimize any potential risk of misuse.

### Scenario D {#s2.4.3}

The impact of non-coverage policies for OTC products was evaluated: following the switch, the Rx status of the switched triptan was removed.

Software {#s2.5}
--------

The model was developed/designed in Microsoft Office Excel 2007.

Results {#s3}
=======

Savings calculated by the model are presented in [Table 4](#pone-0084088-t004){ref-type="table"}. From the TPP perspective, the model estimates that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is €582 million annually. That includes the cost of reimbursed triptans, GP visits and ER visits. The estimated annual direct savings to public healthcare budgets associated with switching are estimated to be €75 million accounting for 12.9% of the overall direct economic burden of migraine (€21.2 million in France, £13.9 million in UK, €11.0 million in Italy, €16.1 million in Germany, PLN 0.3 million in Poland and €10.2 million in Spain). From the societal perspective, current overall spending on migraine management is €3,489 million annually, and estimated savings are estimated at €86 million annually, accounting for 2.5% of the budget (€25.4 million in France, £15.7 million in UK, €12.0 million in Italy, €19.0 million in Germany, PLN 0.7 million in Poland and €10.9 million in Spain).

10.1371/journal.pone.0084088.t004

###### Base case analysis results.

                                                     **Direct costs/savings**   **Indirect costs/savings**   **TOTAL costs**   **TOTAL costs**                                                                                           
  -------------------------------------------------- -------------------------- ---------------------------- ----------------- ----------------- -------- ---------- ------------ ------------- --------------- ---------- ------------- ---------------
  France                                             Costs before the switch    89,283,831                   53,749,696        10,426,799                            27,149,704   361,321,298   475,922,844                153,460,326   1,017,854,172
  (€2010)                                            Costs after the switch     71,427,065                   50,524,714        10,257,312        872      30,279     25,520,722   359,510,261   474,983,011     233,411    132,240,243   992,487,648
                                                     Total savings              17,856,766                   3,224,982         169,486           -872     -30,279    1,628,982    1,811,037     939,832         -233,411   21,220,083    25,366,524
                                                     Costs before the switch    56,233,629                   41,056,361        15,168,153                            11,022,317   146,690,285   354,379,442                112,458,143   624,550,187
  UK (£2010)                                         Costs after the switch     44,986,903                   38,592,979        14,967,686        677      35,106     10,360,978   145,955,035   353,771,477     143,834    98,583,351    608,814,675
                                                     Total savings              11,246,726                   2,463,382         200,467           -677     -35,106    661,339      735,250       607,965         -143,834   13,874,792    15,735,512
  Italy                                              Costs before the switch    49,865,795                   14,705,495        14,882,863                            6,651,217    88,517,593    261,829,545                79,454,153    436,452,509
  (€2010)                                            Costs after the switch     39,892,636                   13,823,166        14,741,253        654      10,586     6,252,144    88,073,920    261,535,332     73,069     68,468,294    424,402,759
                                                     Total savings              9,973,159                    882,330           141,610           -654     -10,586    399,073      443,673       294,213         -73,069    10,985,859    12,049,750
  Germany                                            Costs before the switch    67,371,768                   41,905,589        16,029,650                            19,451,314   258,867,418   474,886,315                125,307,007   878,512,054
  (€2010)                                            Costs after the switch     53,897,414                   39,391,254        15,855,573        819      18,709     18,284,235   257,569,907   474,352,694     132,527    109,163,769   859,503,132
                                                     Total savings              13,474,354                   2,514,335         174,077           -819     -18,709    1,167,079    1,297,512     533,621         -132,527   16,143,238    19,008,923
  Poland                                             Costs before the switch                                 2,742,272         17,343,966                            1,393,251    18,542,057    234,747,009                20,086,238    274,768,556
  (PLN 2010)                                         Costs after the switch                                  2,577,736         17,212,552        298      8,449      1,309,656    18,449,119    234,483,229     65,511     19,799,035    274,106,550
                                                     Total savings                                           164,536           131,414           -298     -8,449     83,595       92,938        263,781         -65,511    287,203       662,006
  Spain                                              Costs before the switch    45,988,181                   12,346,284        24,924,237                            4,491,924    59,780,684    188,233,144                83,258,702    335,764,454
  (€2010)                                            Costs after the switch     36,790,545                   11,605,507        24,690,627        677      9,461      4,222,409    59,481,047    188,021,630     52,530     73,096,817    324,874,433
                                                     Total savings              9,197,636                    740,777           233,609           -677     -9,461     269,515      299,637       211,514         -52,530    10,161,885    10,890,021
  Total                                              Costs before the switch    320,260,935                  172,846,336       88,799,849                            71,366,381   949,778,064   1,885,512,429              581,907,120   3,488,563,994
  (€2010) [\*\*\*](#ngtab4.3){ref-type="table-fn"}   Costs after the switch     256,208,748                  162,475,556       87,807,250        3,911    113,407    67,084,399   945,017,528   1,882,735,949   680,927    506,608,872   3,402,127,675
                                                     Total savings              64,052,187                   10,370,781        992,597           -3,911   -113,407   4,281,982    4,760,537     2,776,479       -680,927   75,298,247    86,436,318

^\*^ Productivity loss due to GP visits to get medication and due to migraine attacks for Pop 1 & Pop 2

^\*\*^ Productivity loss due to migraine attacks for Pop 3 & Pop 4

^\*\*\*^ All costs have been converted into €2010, using with the following rates: €1 = PLN 4.07 PLN (06/2010), €1= £ 0.83 (06/2010)

CV=cardiovascular, GP=General Practitioner, MOH=medication over use

The majority of savings (85% for TPP perspective and 74% from societal perspective) comes from drug acquisition costs that are shifted from payers to patients. GP visits avoided contribute for 14% of direct savings and ER visits avoided for 1%. Additional cardiovascular events and additional GP visits due to MOH had a negligible impact on budget.

When considering the societal perspective, productivity loss due to migraine management (GP visits to get medication and due to migraine attacks for Pop 1 & Pop 2, and due to migraine attacks for Pop 3 & Pop 4) or account for 81% of current spending.

The additional cost implications resulting from a (potential) slight increase in the risk of AE due to a lack of doctor's supervision are negligible: €0.11 million in direct costs plus an estimated €0.68 million of productivity losses, mainly from additional physician visits from patients that will develop MOH.

The employer benefits account for a total of 14% (or €11 million) and are similar in size to the savings that result from avoided GP visits. There are 3 major sources of the employer benefits:

1.  Time taken off work for patients to obtain a prescription for Rx triptan to be switched- sick leave

2.  Productivity gains due to convenient access to switched triptan for patients who previously had to obtain a prescription for switched triptan

3.  Productivity gains due to increased access to switched triptan in untreated patients or those currently treated with an OTC product

Sensitivity analysis {#s3.1}
--------------------

The model has shown to be particularly sensitive to switch rates across different patient groups. In scenario A it was assumed that diagnosed patients treated with Rx triptan (Pop 1 & Pop 2) would not switch to OTC triptan to be switched and thus switch rates were decreased to 0% instead of 20%. An unfavorable impact on the results is found for all countries. For example, in France, the savings fell from 13.83% and 2.49% to 0.05% and 0.08% for TPP and societal perspectives respectively.

In scenario B, where it was assumed that undiagnosed patients would switch to OTC triptan to be switched: switch rates for undiagnosed populations (Pop 5 & Pop 6) were increased to 3% instead of 0%, a favorable impact on the results is seen for all countries. As an example, in the UK, the savings increased from 12.34% to 12.43% for TPP perspective and from 2.52% to 2.61% for societal perspective.

The results of the scenario C suggest the model is insensitive to the costs of cardiovascular events due to its rare frequency. Considering 90% decrease instead of 95% decrease in risk of cardiovascular event has a negligible impact.

Finally, the scenario D shows that the introduction of the disreimbursement policies resulted in additional drug savings to the healthcare budget holder. Overall, savings increased from €75 million to around €86 million for TPP perspective and from €86 million to around €100 million from societal perspective.

Discussion {#s4}
==========

A triptan Rx-to-OTC switch represents a way for payers to manage spending. This is particularly relevant at a time of cash-strapped healthcare budgets across Europe. Seventy-five percent of the cost savings (€64 million) come from shifting drug costs from payers to patients. Such savings are easily and quickly realized. In contrast, other cost savings such as avoided GP or ER visits, although important, are not necessarily easy to realize in some EU countries as primary care doctors are paid a flat annual fee regardless of the number of patient visits.

Enhanced availability of OTC medicines can provide patients easier access to effective and safe drugs, implying a reduction in the number of days with significantly impaired work productivity across the 6 EU Member States. Our model estimates that 830,000 patients of all migraine sufferers will be purchasing the OTC triptan when it reaches the forecast peak sales. Almost half of the usage of the OTC triptan (46%) is estimated to be among patients that are currently treated with partially effective OTC analgesics or those who are not treated at all. It is possible to further reduce the disease burden, if manufacturers invest in a disease awareness campaign that will promote awareness of the condition to currently undiagnosed patients (40% of all migraine sufferers).

Given that the majority of cost savings come from reduced spending by payers on triptans, the highest level of savings would be generated in countries where triptans are currently reimbursed at 100% without patient co-payments. In countries where triptans are not reimbursed, such as Poland, the economic benefits would be non-negligible but far lower.

The model estimates that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is €582 million. That includes the cost of reimbursed triptans, GP visits and ER visits. The estimated direct savings associated with switching one triptan are estimated to be €75 million accounting for 13% of the overall direct economic burden of migraine.

Should the price of OTC triptan be attractive, we estimate that 20% of patients currently taking the Rx triptan product will switch to OTC triptan, and the societal economic benefits will be around €86 million in the 6 EU Member States. In case patients perceive the OTC price as being too high, they may prefer to visit a primary care doctor to obtain a prescription and pay only a (nominal) co-payment or a dispensing fee for the reimbursed product.

Several limitations are to be noted. First, our model did not include implications of a possible misdiagnosis of serious disease and wastage of resources in patients for whom OTC treatment is inappropriate. This model also assumed the switch rate would be the same for all countries, as no relevant literature providing evidence of country-specific behaviour was found. Finally, it is not excluded that there might be a perverse incentive; currently patients are used to getting 'free triptan' from 'free GP visit', but after the Rx-to-OTC switch, they will have to pay to get the OTC medicine. This may incite patients to be prescribed more expensive 'free' medicine (like higher doses of triptan, other Rx triptans, or even morphine). All these points were discussed with experts and impact was assumed to be negligible.

Conclusions {#s5}
===========

The results of the model suggest that the switch of a triptan to the OTC status is likely to result in substantial economic benefits of which the majority could be quickly realized by payers across the 6 investigated EU countries. Around 74% of the economic benefits come from lower spending on the Rx triptan when considering societal perspective. These savings are likely to be bigger is all 27 EU member states are considered. Given that the majority of the savings come from the avoided drug acquisition cost, they would be mainly generated in countries where the triptan is currently reimbursed.
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